Raludotatug Deruxtecan
默沙东/第一三共CDH6靶向ADC Raludotatug Deruxtecan获FDA突破性疗法认定
默沙东与第一三共联合开发的CDH6靶向ADC Raludotatug Deruxtecan（R-DXd）获FDA突破性疗法认定。早期临床显示ORR 46%，DCR 98%，彰显潜力。
Raludotatug Deruxtecan
默沙东与第一三共联合开发的CDH6靶向ADC Raludotatug Deruxtecan（R-DXd）获FDA突破性疗法认定。早期临床显示ORR 46%，DCR 98%，彰显潜力。
Raludotatug Deruxtecan
The FDA has granted Breakthrough Therapy Designation to Raludotatug Deruxtecan (R-DXd), a CDH6-targeting ADC, for patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Early-phase trials show ORR 46% and DCR 98%.